Introduction Navigating FDA vs EMA biosimilar regulatory pathways is one of the most strategically consequential decisions a biopharmaceutical developer makes […]
Introduction Within the highly specialized field of drug development, implementing advanced Bioanalytical Services for Rare Disease programs is essential for
Process vs. Material Origins Nitrosamine impurities originate from active pharmaceutical ingredient (API) synthetic pathways, degraded raw materials, or chemical interactions
What Is the Difference Between a Nitrosamine Impurity and a Nitrosamine Leachable? Read More »
The Regulatory Imperative for a Peptide Characterization CRO Deliverables Checklist A peptide characterization CRO deliverables checklist serves as a fundamental
Introduction: Biosimilar development guide breaks down every stage of the journey, from initial molecule selection and reference product characterization through
What is Biosimilar Development? A Step-by-Step Guide from Molecule to Market Read More »
Introduction to Encapsulating Hydrophilic vs Hydrophobic APIs in PLGA The development of clinically successful long-acting parenteral formulations depends on aligning
Encapsulating Hydrophilic vs Hydrophobic APIs in PLGA: Key Formulation Differences Read More »
Assessing the chemical safety of human drug products requires a thorough understanding of potential mutagenic and carcinogenic impurities that fall
Navigating Clinical Translation of CNS Small Molecules Under FDA Fast Track The clinical translation of central nervous system (CNS)-active small
Introduction: In peptide drug development, the quality of your analytical data is only as good as the reference standard anchoring
Identifying and addressing the root causes of failed Extractables and Leachables (E&L) studies has become a critical regulatory requirement for
